The mixed quarter — revenue beat but EPS miss and lowered EPS growth guidance — suggests limited near-term upside. Watch Q4 for sequential operational improvement and margin recovery; the 2.4x leverage target achieved provides some downside protection. The reaffirmed EBITDA guidance keeps the FY range intact, but the EPS downgrade signals tax headwinds that may cap earnings momentum into fiscal 2027.
Price Chart
Executive Summary
Ashland reported Q3 2026 EPS of $0.91, missing consensus of $0.98 by 7.1%, while revenue of $497M beat the $486M estimate by 2.3%. Sales grew 7% YoY driven by volume gains across all segments, but adjusted EBITDA fell 4% YoY to $109M due to operational challenges and cost pressures. The company reaffirmed full-year sales and EBITDA guidance but lowered its adjusted EPS growth outlook to low-to-mid single digits, reflecting a higher tax rate, capping the upside from the revenue beat.
Key Financial Metrics
Key Facts
- EPS of $0.91 missed consensus of $0.98 (-7.1%)
- Revenue of $497M beat consensus of $486M (+2.3%) and grew 7% YoY
- Adjusted EBITDA of $109M declined 4% YoY; margin was 21.9%
- Life Sciences sales +11% YoY; Personal Care +5%; Specialty Additives +4%; Intermediates +12%
- Full-year sales guidance reaffirmed at $1,835-$1,870M; EBITDA guidance reaffirmed at $385-$400M
- Adjusted EPS growth outlook lowered to low-to-mid single digits from mid-to-high single digits
- Ongoing Free Cash Flow of $103M vs $108M prior year; net leverage at 2.4x
- Cash from operations $121M, up from $114M prior year
Financial Impact
EPS miss of $0.07 (-7.1%) vs consensus; revenue beat of $11M (+2.3%); adjusted EBITDA down $4M YoY
Risk Factors
- Lowered adjusted EPS growth guidance signals higher tax rate headwinds
- Adjusted EBITDA declined 4% YoY despite revenue growth, reflecting operational cost pressures
- Specialty Additives and Intermediates segments saw year-over-year EBITDA declines
- Macroeconomic uncertainty and elevated raw material/freight costs persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334808 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $74.17 $70.27 | ▼ −5.26% | ▼ −3.28% | $69.13 (−6.80%) |
Jul 28, 2026 9w ago | Press Release | $72.84 $74.32 | ▲ +2.03% | ▼ −2.99% | $69.13 (−5.10%) |
Jul 14, 2026 11w ago | Press Release | $68.27 $74.72 | ▲ +9.45% | ▲ +7.11% | $69.13 (+1.25%) |
Jun 11, 2026 16w ago | Institutional Cluster | $65.53 $65.00 | ▼ −0.81% | ▼ −2.70% | $69.13 (+5.49%) |
May 29, 2026 18w ago | 8-K | $57.48 $64.23 | ▲ +11.74% | ▲ +13.54% | $69.13 (+20.26%) |
May 18, 2026 19w ago | 3 | $54.28 $64.36 | ▲ +18.56% | ▲ +17.58% | $69.13 (+27.34%) |
May 5, 2026 21w ago | Press Release | $54.59 $57.00 | ▲ +4.41% | ▲ +1.63% | $69.13 (+26.63%) |
Apr 28, 2026 22w ago | Press Release | $48.79 $56.90 | ▼ −16.62% | ▼ −10.57% | $69.13 (−41.67%) |
Apr 15, 2026 24w ago | Press Release | $57.47 $56.50 | ▼ −1.69% | ▼ −7.50% | $69.13 (+20.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access